Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.

Authors	Nicholas J Short, Walid Macaron, Marina Konopleva, Farhad Ravandi, Nitin Jain, Ghayas C Issa, Tapan Kadia, Koji Sasaki, Partow Kebriaei, Musa Yilmaz, Philip A Thompson, Koichi Takahashi, Hussein A Abbas, William G Wierda, Rebecca Garris, Hagop M Kantarjian, Elias Jabbour
Journal	American journal of hematology (Am J Hematol) Vol. 97 Issue 6 Pg. E201-E204 (06 01 2022) ISSN: 1096-8652 [Electronic] United States
PMID	35266566 (Publication Type: Letter, Research Support, N.I.H., Extramural)
Chemical References	Antibodies, Bispecific blinatumomab Inotuzumab Ozogamicin
Topics	Antibodies, Bispecific (adverse effects) Humans Inotuzumab Ozogamicin Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!